Table 2. Effects on complement-mediated... | American Society of Hematology

Table 2.

Effects on complement-mediated cytotoxicity of blocking CD46, CD55, and CD59

Conditions	DHL-4	Karpas	WSU-NHL	BJAB
Medium	0^*	0	0	0
NHS^†	0.8	2	2.3	1.3
R^‡ + NHS	62.4	7.8	48.2	55.4
R + NHS + anti-CD55	75	39.9	56.8	73.8
R + NHS + anti-CD46	54.8	0.7	46.8	56.7
R + NHS + anti-CD59	83.7	5.6	67.5	61.4
R + NHS + anti-CD55/CD59	83.9	26.8	90.6	95.9

Conditions	DHL-4	Karpas	WSU-NHL	BJAB
Medium	0^*	0	0	0
NHS^†	0.8	2	2.3	1.3
R^‡ + NHS	62.4	7.8	48.2	55.4
R + NHS + anti-CD55	75	39.9	56.8	73.8
R + NHS + anti-CD46	54.8	0.7	46.8	56.7
R + NHS + anti-CD59	83.7	5.6	67.5	61.4
R + NHS + anti-CD55/CD59	83.9	26.8	90.6	95.9

The data are the % lysed cells above that of the untreated control. They are representative of 3 independent experiments.

Normal human serum (NHS) was used at 25% for all cell lines, except for DHL-4 in which 5% was added.

R: 2 μg/mL rituximab.